Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The R337C mutation generates a high Km 11 beta-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess.

The Journal of clinical endocrinology and metabolism - 1 Nov 1995

Obeyesekere V R, Ferrari P, Andrews R K, Wilson R C, New M I, Funder J W, Krozowski Z S

Abstract excerpt

The 11 beta-hydroxysteroid dehydrogenase type II enzyme (11 beta HSD2) inactivates glucocorticoids in the kidney and thus permits aldosterone to occupy the non-selective mineralocorticoid receptor in epithelial tissues. We have recently described a C to T transition in the HSD11B2 gene which results in an arginine to cysteine mutation (R337C) in the 11 beta HSD2 enzyme in a consanguineous family with three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Base Sequence
Share to Hydrocortisone

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hydroxysteroid Dehydrogenases

Share to Mineralocorticoids

Share to Molecular Sequence Data

Share to Mutation

Share to Oligonucleotide Probes

Source

Identifiers

PMID: 7593456
DOI: 10.1210/jcem.80.11.7593456

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The R337C mutation generates a high Km 11 beta-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess.PMID 7593456Read ↗

The 11 beta-hydroxysteroid dehydrogenase type II enzyme: biochemical consequences of the congenital R337C mutation.Semantic proximity Read ↗

Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.Semantic proximity Read ↗

Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene.Semantic proximity Read ↗

Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess.Semantic proximity Read ↗

A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.Semantic proximity Read ↗

In vitro expression studies of a novel mutation delta299 in a patient affected with apparent mineralocorticoid excess.Semantic proximity Read ↗

Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.Semantic proximity Read ↗

Apparent mineralocorticoid excess: report of six new cases and extensive personal experience.Semantic proximity Read ↗

Apparent mineralocorticoid excess (AME) syndrome.Semantic proximity Read ↗

Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.Semantic proximity Read ↗

Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.Semantic proximity Read ↗

A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.